With the advent of technology, we are cocksure to upgrade ourselves not only to fear that we would turn obsolete soon but also to accomplish the objective of organizational Good pharmacovigilance practices.
For any drug that sees light of the day, there are case studies that will be published, research and review articles that would be written by the researchers working to discover the yet unknown or to confirm the trial findings on a pivotal scale.
The existence of each of these literature of interest will ultimately be cycled to manage the regulatory reporting and document the literature screening activity, as an essential part of routine pharmacovigilance surveillance.